The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study.
Charles L. Loprinzi
No relevant relationships to disclose
Rui Qin
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Louis Fehrenbacher
No relevant relationships to disclose
Philip J. Stella
No relevant relationships to disclose
Pamela J. Atherton
No relevant relationships to disclose
Drew K. Seisler
No relevant relationships to disclose
Rubina Qamar
No relevant relationships to disclose
Grant Carlton Lewis
No relevant relationships to disclose
Axel Grothey
No relevant relationships to disclose